Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest

Thrombosis and Haemostasis

Volumn 94, Issue 1, 2005, Pages 115-122

  Straub, Andreas ^a   Azevedo, Ruben ^a   Beierlein, Wolfram ^a   Wendel, Hans P ^a   Dietz, Klaus ^a   Ziemer, Gerhard ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cell cell interactions; Coagulation inhibitors; Platelet pharmacology; Platelet physiology

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; PROTEIN ANTIBODY; TIROFIBAN;

ARTICLE; CELL INTERACTION; CONTROLLED STUDY; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HYPOTHERMIA; INHIBITION KINETICS; LEUKOCYTE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANTICOAGULANTS; BLOOD PLATELETS; CARDIOPULMONARY BYPASS; CELL ADHESION; FEVER; FLOW CYTOMETRY; GRANULOCYTES; HUMANS; HYPOTHERMIA, INDUCED; LEUKOCYTES; MALE; P-SELECTIN; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; TEMPERATURE; THROMBOSIS; TIME FACTORS;

EID: 22144486965     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-10-0641     Document Type: Article

References (30)

1. Ergin MA, Uysal S, Reich DL et al. Temporary neurological dysfunction after deep hypothermic circulatory arrest: a clinical marker of long-term functional deficit. Ann Thorac Surg 1999; 67: 1887-90; discussion 1891-4.
2. Bellinger DC, Jonas RA, Rappaport LA et al. Developmental and neurologic status of children after heart surgery with hypothermic circulatory arrest or low-flow cardiopulmonary bypass. N Engl J Med 1995; 332: 549-55.
3. Newburger JW, Jonas RA, Wernovsky G et al. A comparison of the perioperative neurologic effects of hypothermic circulatory arrest versus low-flow cardiopulmonary bypass in infant heart surgery. N Engl J Med 1993; 329: 1057-64.
4. Jonas RA. Deep hypothermic circulatory arrest: Current status and indications. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002; 5: 76-88.
5. Di Eusanio M, Wesselink RM, Morshuis WJ et al. Deep hypothermic circulatory arrest and antegrade selective cerebral perfusion during ascending aorta-hemiarch replacement: a retrospective comparative study. J Thorac Cardiovasc Surg 2003; 125: 849-54.
6. Tassani P, Barankay A, Haas F et al. Cardiac surgery with deep hypothermic circulatory arrest produces less systemic inflammatory response than low-flow cardiopulmonary bypass in newborns. J Thorac Cardiovasc Surg 2002; 123: 648-54.
7. Hall MW, Goodman PD, Alston SM et al. Hypothermia-induced platelet aggregation in heparinized flowing human blood: identification of a high responder subpopulation. Am J Hematol 2002; 69: 45-55.
8. Faraday N, Rosenfeld BA. In vitro hypothermia enhances platelet GPIIb-IIIa activation and P-selectin expression. Anesthesiology 1998; 88: 1579-85.
9. Straub A, Azevedo R, Beierlein W et al. Hypothermia induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin). Thorac Cardiovasc Surg 2005; 53: 80-4.
10. Doré M. Platelet-leukocyte interactions. Am Heart J 1998; 135(5 Pt 2 Su): S146-51.
11. Taylor KM. Brain damage during cardiopulmonary bypass. Ann Thorac Surg 1998; 65(4 Suppl): S20-6; discussion S27-8.
12. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.
13. Schrör K and Weber AA. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 2003; 15: 71-80.
14. Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin Ther 2003; 25: 2564-74.
15. Schneider DJ, Herrmann HC, Lakkis N et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol 2003; 91: 334-6.
16. Jy W, Horstman LL, Park H et al. Platelet aggregates as markers of platelet activation: characterization of flow cytometric method suitable for clinical applications. Am J Hematol 1998; 57: 33-42.
17. Abrams CS, Ellison N, Budzynski AZ et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-38.
18. Bartlett MS. The use of transformations. Biometrics 1947; 3: 39-52.
19. Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999; 84: 203-7.
20. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-46.
21. Peter K, Schwarz M, Ylanne J et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
22. Yeo EL, Sheppard JA, Feuerstein IA. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model). Blood 1994; 83: 2498-507.
23. Davenpeck KL, Brummet ME, Hudson SA et al. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGL-1, CD162) and adhesion to P-selectin in vitro. J Immunol 2000; 165: 2764-72.
24. Diacovo TG, Roth SJ, Buccola JM et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-57.
25. Dore M. Platelet-leukocyte interactions. Am Heart J 1998; 135(5 Pt 2 Suppl): S146-51.
26. Koster A, Chew DP, Kuebler W et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91: 346-7.
27. Straub A, Wendel HP, Azevedo R et al. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Eur J Cardiothorac Surg 2005; 27: 617-21.
28. Bizzarri F, Scolletta S, Tucci E et al. Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122: 1181-5.
29. Dyke CM, Bhatia D, Lorenz TJ et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000; 70: 866-71; discussion 871-2.
30. Hiramatsu Y, Gikakis N, Anderson HL, 3rd et al. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg 1997; 113: 182-93.